Aurobindo Pharma Limited has informed the Exchange about ppdate on entering into a binding agreement for transfer of shares of CuraTeQ Biologics s.r.o., by Helix Healthcare B.V., to Curateq Biologics B.V., wholly owned subsidiaries of the Company
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma has informed exchanges that the transfer of shares of CuraTeQ Biologics s.r.o. from one of its Dutch subsidiaries, Helix Healthcare B.V., to another Dutch subsidiary, Curateq Biologics B.V., has been delayed. A binding agreement for this internal share transfer was signed on July 29, 2025, with an original completion deadline of August 31, 2025. The new deadline is September 30, 2025, as the company is awaiting an updated business register from authorities in The Netherlands to formalise the transfer. Both entities involved are wholly-owned subsidiaries of Aurobindo Pharma, making this an internal restructuring rather than a third-party transaction.
This is a procedural update on an internal group restructuring between wholly-owned subsidiaries. Shareholders are unlikely to see any meaningful impact on financials or stock price, as it is essentially a paper transfer within the Aurobindo group.